Latest Strategy Changes News

NextEd Group Limited reported a 16.7% rise in underlying EBITDA and a 92% reduction in NPAT loss for H1 FY26, underpinned by AI integration and a strategic shift to higher-margin education segments.

Light & Wonder, Inc. reported robust full-year 2025 financial results, highlighted by record revenues, strong cash flow growth, and a major litigation settlement. The company also completed its transition to a sole ASX listing and returned $877 million to shareholders through share repurchases.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.

Meridian Energy has reported a robust turnaround with a NZD 227 million net profit after tax for the first half of 2026, driven by record wind generation and strong hydro inflows. The company also raised its interim dividend and advanced multiple renewable projects.

Tian An Australia Limited reported a remarkable turnaround in FY2025, posting a statutory profit of $23.4 million on $84 million revenue, driven by the completion of The Henley, Enfield project and a significant gain from debt restructuring.

Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.

Timah Resources Limited reported a 24% revenue decline and a narrow profit turnaround in 2025, overcoming a lengthy biogas plant shutdown caused by a critical equipment failure. Operational efficiency gains and risk mitigation efforts underpin the company’s cautious optimism.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Wagners Holding Company Limited has reported a robust half-year result for December 2025, with revenue climbing to $251.7 million and net profit after tax soaring 70% to $21 million. Improved margins and operational efficiencies across key segments underpin the strong performance.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.